Gamida Cell (NASDAQ:GMDA) and Its Rivals Head to Head Comparison

Gamida Cell (NASDAQ: GMDA) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Gamida Cell to similar companies based on the strength of its valuation, institutional ownership, profitability, earnings, risk, analyst recommendations and dividends.

Insider and Institutional Ownership

1.8% of Gamida Cell shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -5,144.22% -64.24% -27.96%

Earnings and Valuation

This table compares Gamida Cell and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -0.79
Gamida Cell Competitors $897.63 million $190.37 million -1.33

Gamida Cell’s rivals have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Gamida Cell and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 834 2773 6056 261 2.58

Gamida Cell presently has a consensus target price of $19.40, indicating a potential upside of 132.34%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.45%. Given Gamida Cell’s stronger consensus rating and higher possible upside, analysts plainly believe Gamida Cell is more favorable than its rivals.

Summary

Gamida Cell beats its rivals on 7 of the 12 factors compared.

About Gamida Cell

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.